Appendix A Program and Technical Description

APPENDIX A: PROGRAM AND TECHNICAL DESCRIPTION

1.

BACKGROUND

The United States depends heavily on global pharmaceutical supply chains for key starting materials, active pharmaceutical ingredients, and finished drug products. As this dependence has grown, the challenge of ensuring the quality and safety of imported pharmaceuticals has also grown with it. Existing oversight tools—including facility inspections and laboratory-based testing—remain essential, but they are stretched to their limits supporting the magnitude and complexity of today’s international supply chains.
Current testing approaches for pharmaceutical quality and contamination are generally labor intensive, destructive, and slow. They work well when used in manufacturing facilities or independent testing labs for quality assurance. Conventional laboratory methods may require samples to be opened, dissolved, or otherwise processed under tightly controlled conditions, often taking weeks to return results. These methods are valuable for confirmation and enforcement too but are not well suited for high-throughput screening at points of entry or other operational environments. At the same time, many FDA warning letters cite data integrity or documentation problems, and the Agency has even made public statements regarding testing labs that have repeatedly provided falsified or misleading data as part of submissions to the agency.
Relying on inspections for quality assurance, a relatively small number of imported pharmaceuticals are selected on a risk-basis for direct quality and safety testing. Often, the same lab methods are used to characterize the products, which increases time and cost burden for all parties. There are several non-contact systems that can detect the presence of certain chemicals, but they have specificity and accuracy limitations, especially through packaging – which limits their ability to provide the data needed for operational decision-making. This creates a critical gap where unsafe, contaminated, adulterated, or substandard pharmaceutical products may enter the U.S. supply chain before defects are identified. Product recalls and adverse event investigations can reduce harm after the fact, but often patient harm is the initiator of recall investigations and more are at risk before recalls can be fully implemented. In one case alone, recalls of key cardiovascular drugs over the last decade have affected 150 million patients on those medications. Problems can range from mislabeling, to